Sarcoidosis | General population | Adjusted rate difference per 1000 person-years^{#}(95% CI) | Hazard ratio^{#}(95% CI) | Adjusted hazard ratio^{#}(95% CI) | |||

Events | Adjusted rate per 1000 person-years^{#}(95% CI) | Events | Adjusted rate per 1000 person-years^{#}(95% CI) | ||||

Subjects | 8737 | 86 376 | |||||

Overall | 895 | 17.4 (16.0–18.9) | 3881 | 9.6 (9.3–9.9) | 7.8 (6.3–9.2) | 2.40 (2.23–2.58) | 1.81 (1.65–1.98) |

Age at inclusion^{¶} years | |||||||

18–44 | 222 | 8.8 (7.4–10.5) | 937 | 5.1 (4.8–5.4) | 3.7 (2.2–5.3) | 2.39 (2.07–2.77) | 1.74 (1.44–2.09) |

45–64 | 327 | 16.1 (14.0–18.5) | 1334 | 8.5 (8.0–8.9) | 7.6 (5.4–9.9) | 2.58 (2.28–2.91) | 1.90 (1.64–2.20) |

65–85 | 346 | 58.3 (51.1–66.4) | 1610 | 27.0 (25.7–28.3) | 31.3 (23.5–39.1) | 2.45 (2.18–2.75) | 2.16 (1.88–2.49) |

Sex^{¶} | |||||||

Female | 435 | 21.6 (19.2–24.3) | 1938 | 10.7 (10.3–11.2) | 10.9 (8.3–13.5) | 2.36 (2.13–2.62) | 2.01 (1.78–2.28) |

Male | 460 | 14.3 (12.7–16.1) | 1943 | 8.7 (8.3–9.1) | 5.6 (3.8–7.4) | 2.45 (2.21–2.71) | 1.64 (1.45–1.87) |

Treatment status around diagnosis^{¶}^{,}^{+} | |||||||

Treated | 326 | 29.8 (25.9–34.3) | 948 | 9.8 (9.2–10.4) | 20.0 (15.8–24.2) | 3.70 (3.26–4.19) | 3.04 (2.61–3.55) |

Not treated | 275 | 15.7 (13.5–18.3) | 1428 | 10.2 (9.7–10.8) | 5.5 (3.1–7.9) | 1.96 (1.72–2.23) | 1.53 (1.31–1.80) |

Data are presented as n, unless otherwise stated. ^{#}: rates and rate differences were estimated using Poisson regression models weighted for inverse probability of sarcoidosis weights. Hazard ratios were estimated using Cox proportional hazards regression models with years of follow-up as the time scale in a cohort matched on age, sex and residential location. Adjusted hazard ratios were estimated using inverse probability of sarcoidosis weights; ^{¶}: p-value for effect measure modification from a likelihood ratio test for the adjusted models: age at inclusion (p=0.10), sex (p=0.01), treatment status around diagnosis (p<0.001); ^{+}: assessed in a subset of individuals who entered the cohort starting January 1, 2006 (treated analysis: sarcoidosis n=2762, general population n=27 325; not treated analysis: sarcoidosis n=3961, general population comparators n=39 116).